• +1-646-491-9876
    • +91-20-67278686

    Search

    Opium (Opioid) Addiction - Pipeline Review, H1 2017

    Opium (Opioid) Addiction - Pipeline Review, H1 2017

    • Report Code ID: RW0001767497
    • Category Pharmaceuticals
    • No. of Pages 104
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Opium (Opioid) Addiction - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2017, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

    Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins) . This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 4, 2, 13 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

    Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 3
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Opium (Opioid) Addiction - Overview 6
    Opium (Opioid) Addiction - Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Pipeline by Universities/Institutes 11
    Products under Development by Companies 12
    Products under Development by Universities/Institutes 14
    Opium (Opioid) Addiction - Therapeutics Assessment 15
    Assessment by Target 15
    Assessment by Mechanism of Action 17
    Assessment by Route of Administration 19
    Assessment by Molecule Type 21
    Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 23
    Alkermes Plc 23
    Aoxing Pharmaceutical Company Inc 23
    Aquilus Pharmaceuticals Inc 24
    BioCorRx Inc 24
    BioDelivery Sciences International Inc 25
    Camurus AB 25
    Foresee Pharmaceuticals LLC 26
    Heron Therapeutics Inc 26
    Indivior Plc 27
    INSYS Therapeutics Inc 28
    Omeros Corp 29
    Opiant Pharmaceuticals Inc 29
    Orexigen Therapeutics Inc 30
    Orexo AB 30
    Pfizer Inc 31
    Relmada Therapeutics Inc 31
    Savant HWP Inc 32
    Teva Pharmaceutical Industries Ltd 32
    Titan Pharmaceuticals Inc 33
    Zynerba Pharmaceuticals Inc 33
    Opium (Opioid) Addiction - Drug Profiles 34
    (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 34
    (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 35
    (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 36
    (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 37
    (buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile 38
    18-MC - Drug Profile 44
    AQU-010 - Drug Profile 46
    buprenorphine hydrochloride - Drug Profile 47
    buprenorphine hydrochloride - Drug Profile 50
    buprenorphine hydrochloride - Drug Profile 51
    buprenorphine hydrochloride depot - Drug Profile 56
    buprenorphine hydrochloride ER - Drug Profile 57
    buprenorphine hydrochloride long acting - Drug Profile 59
    buprenorphine hydrochloride SR - Drug Profile 60
    cannabidiol - Drug Profile 63
    cannabidiol - Drug Profile 64
    Canquit-O - Drug Profile 67
    FP-004 - Drug Profile 68
    naltrexone hydrochloride - Drug Profile 69
    naltrexone hydrochloride - Drug Profile 70
    naltrexone hydrochloride SR - Drug Profile 71
    OMS-405 - Drug Profile 73
    OMS-527 - Drug Profile 75
    OREX-1019 - Drug Profile 77
    ORP-107 - Drug Profile 78
    PF-4363467 - Drug Profile 79
    PF-5006739 - Drug Profile 80
    Small Molecule to Antagonize D3 Receptor for Opioid Addiction - Drug Profile 81
    TEV-90109 - Drug Profile 82
    Vaccine for Opioid Addiction - Drug Profile 83
    Vaccine for Opium Addiction - Drug Profile 84
    Opium (Opioid) Addiction - Dormant Projects 85
    Opium (Opioid) Addiction - Discontinued Products 86
    Opium (Opioid) Addiction - Product Development Milestones 87
    Featured News & Press Releases 87
    Appendix 100
    Methodology 100
    Coverage 100
    Secondary Research 100
    Primary Research 100
    Expert Panel Validation 100
    Contact Us 100
    Disclaimer 101

    List of Tables

    Number of Products under Development for Opium (Opioid) Addiction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H1 2017
    Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by Aquilus Pharmaceuticals Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by Camurus AB, H1 2017
    Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
    Opium (Opioid) Addiction - Pipeline by Heron Therapeutics Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by Indivior Plc, H1 2017
    Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by Omeros Corp, H1 2017
    Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by Orexigen Therapeutics Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by Orexo AB, H1 2017
    Opium (Opioid) Addiction - Pipeline by Pfizer Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by Savant HWP Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
    Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc, H1 2017
    Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
    Opium (Opioid) Addiction - Dormant Projects, H1 2017
    Opium (Opioid) Addiction - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Opium (Opioid) Addiction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Alkermes Plc
    Aoxing Pharmaceutical Company Inc
    Aquilus Pharmaceuticals Inc
    BioCorRx Inc
    BioDelivery Sciences International Inc
    Camurus AB
    Foresee Pharmaceuticals LLC
    Heron Therapeutics Inc
    Indivior Plc
    INSYS Therapeutics Inc
    Omeros Corp
    Opiant Pharmaceuticals Inc
    Orexigen Therapeutics Inc
    Orexo AB
    Pfizer Inc
    Relmada Therapeutics Inc
    Savant HWP Inc
    Teva Pharmaceutical Industries Ltd
    Titan Pharmaceuticals Inc
    Zynerba Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//opium-opioid-addiction-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//opium-opioid-addiction-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//opium-opioid-addiction-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments